Literature DB >> 17242654

Preoperative autologous blood donation - part II. Adapting the predeposit concept to the physiological basics of erythropoiesis improves its efficacy.

G Singbartl1, S Malgorzata, A Quoss.   

Abstract

AIM: Only two clinical parameters have been demonstrated to be of decisive impact on efficacy [i.e. increase in red blood cell (RBC)]-mass] of the autologous predeposit; the time interval between predeposit and elective surgery that correlates positively with increase in RBC-mass, and the haematocrit-level at predeposit that correlates negatively with it. These two determinants of efficacy might be applied most efficaciously by combining them within one predeposit-session.
METHODS: Prospective study concerning the efficacy of two different autologous predeposit-concepts in osteoarthritis (n=160) and rheumatoid arthritis patients (n=74); the conventional ''two separately collected units concept'' (one RBC-unit each on two separate predeposit-sessions) and the new ''one double deposit'' concept (two RBC-units on one predeposit-session). The increase in RBC-mass was calculated with the haematocrit-method. Statistical analysis by ANOVA with post-hoc-test to Scheffé/H-test, and U-test; P<0.05 with Bonferroni-correction when appropriate.
RESULTS: In either group of patients, increase in RBC-mass was higher with the new than the conventional predeposit concept (osteoarthritis: 261+/-114 vs 168+/-133 mL; P<0.000; rheumatoid arthritis: 239+/-112 vs 149+/-152 mL; P=0.039). Efficacy of either concept between osteoarthritis and rheumatoid arthritis patients was not different (new concept: 261+/-114 vs 238+/-112; P=0.765; conventional concept: 168+/-133 vs 149+/-152; P=0.941).
CONCLUSIONS: An autologous predeposit-concept considering the physiological basics of erythropoiesis (i.e. long time-interval between predeposit and elective surgery for RBC-regeneration, and a low haematocrit-level at/after autologous predeposit in order to stimulate erythrpoiesis) enhances RBC-recovery in a clinically relevant extent both in osteoarthritis and rheumatoid arthritis patients. Concerning efficacy of autologous predeposit, no differences were demonstrated between osteoarthritis and rheumatoid arthritis patients.

Entities:  

Mesh:

Year:  2007        PMID: 17242654

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  6 in total

Review 1.  Autologous blood in obstetrics: where are we going now?

Authors:  Giancarlo Maria Liumbruno; Chiara Liumbruno; Daniela Rafanelli
Journal:  Blood Transfus       Date:  2011-10-25       Impact factor: 3.443

2.  Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

Authors:  Stefania Vaglio; Domenico Prisco; Gianni Biancofiore; Daniela Rafanelli; Paola Antonioli; Michele Lisanti; Lorenzo Andreani; Leonardo Basso; Claudio Velati; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2015-12-15       Impact factor: 3.443

3.  Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-04       Impact factor: 3.443

4.  10 Autologous Hemotherapy.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 5.  Pre-operative autologous blood donation: clinical parameters and efficacy.

Authors:  Günter Singbartl
Journal:  Blood Transfus       Date:  2011-01       Impact factor: 3.443

6.  Indications and organisational methods for autologous blood transfusion procedures in Italy: results of a national survey.

Authors:  Liviana Catalano; Alessandra Campolongo; Maurizio Caponera; Alessandra Berzuini; Andrea Bontadini; Giuseppe Furlò; Patrizio Pasqualetti; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.